Phase 1 Study of a Notch Inhibitor in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2016
At a glance
- Drugs LY 900009 (Primary)
- Indications Lymphoma; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly
- 19 Jan 2016 Results published in the European Journal of Cancer.
- 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.